Document Detail

Biopharmaceuticals derived from genetically modified plants.
MedLine Citation:
PMID:  15496527     Owner:  NLM     Status:  MEDLINE    
Modern biotechnology has resulted in a resurgence of interest in the production of new therapeutic agents using botanical sources. With nearly 500 biotechnology products approved or in development globally, and with production capacity limited, the need for efficient means of therapeutic protein production is apparent. Through genetic engineering, plants can now be used to produce pharmacologically active proteins, including mammalian antibodies, blood product substitutes, vaccines, hormones, cytokines, and a variety of other therapeutic agents. Efficient biopharmaceutical production in plants involves the proper selection of host plant and gene expression system, including a decision as to whether a food crop or a non-food crop is more appropriate. Product safety issues relevant to patients, pharmaceutical workers, and the general public must be addressed, and proper regulation and regulatory oversight must be in place prior to commercial plant-based biopharmaceutical production. Plant production of pharmaceuticals holds great potential, and may become an important production system for a variety of new biopharmaceutical products.
D A Goldstein; J A Thomas
Related Documents :
23717317 - When stress and development go hand in hand: main hormonal controls of adventitious roo...
22580697 - The role of flavonoids in the establishment of plant roots endosymbioses with arbuscula...
24405887 - Silicon mitigates heavy metal stress by regulating p-type heavy metal atpases, oryza sa...
24134887 - Rapid ammonia gas transport accounts for futile transmembrane cycling under nh3/nh4+ to...
18597907 - Plutonium isotopes in surface air of prague in 1986-2006.
6645577 - Rwandese herbal remedies used against gonorrhoea.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  QJM : monthly journal of the Association of Physicians     Volume:  97     ISSN:  1460-2725     ISO Abbreviation:  QJM     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-10-21     Completed Date:  2005-03-24     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9438285     Medline TA:  QJM     Country:  England    
Other Details:
Languages:  eng     Pagination:  705-16     Citation Subset:  IM    
Monsanto Company A2NE, 800 N. Lindbergh Blvd, St Louis, MO 63167, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies / metabolism
Biotechnology / methods
Drug Industry*
Plants, Genetically Modified / metabolism*
Recombinant Proteins / biosynthesis*
Technology, Pharmaceutical / methods
Vaccines / biosynthesis
Reg. No./Substance:
0/Antibodies; 0/Recombinant Proteins; 0/Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Probing microRNAs with microarrays: tissue specificity and functional inference.
Next Document:  Life-threatening envenoming by the Saharan horned viper (Cerastes cerastes) causing micro-angiopathi...